SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics ($ATRA) is experiencing a significant downturn and intense community discussion after receiving a Complete Response Letter (CRL) from the FDA for its EBVALLO BLA, citing issues solely related to a third-party manufacturing facility rather than the drug's clinical efficacy or safety. While many express frustration over the unexpected delay and potential for dilution, a substantial portion of the community views this as an "overreaction" and a strategic buying opportunity, given the drug's existing approval in Europe and the high unmet medical need. Attention is now focused on the timeline for resolving manufacturing concerns, potential resubmission, and the company's exploration of strategic alternatives, including a possible acquisition by its partner, Pierre Fabre.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending lower amid a Bank of America downgrade citing over-optimistic forward estimates and heightened competitive concerns as Amazon Pharmacy now offers Novo Nordisk's popular weight-loss pill, which is notably absent from HIMS's platform. This is fueling a heated debate, with many viewing the dip as a long-term buying opportunity given HIMS's personalized healthcare and vertical integration strategy, while others anticipate further declines due to competitive pressures and regulatory scrutiny.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent showcases of its advanced agentic and voice AI solutions at a major tech conference, drawing significant community discussion around new partnerships in automotive and robotics. Investors are also actively debating the company's unique technology, which emphasizes client data privacy, and its substantial short interest.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is highly discussed following new AI partnerships with Google, which integrate Gemini for enhanced shopping experiences and expand drone delivery services. The community is actively buzzing about this strategic pivot, viewing WMT increasingly as a tech-enabled retailer ahead of its anticipated Nasdaq-100 inclusion. This narrative emphasizes Walmart's innovation and evolving market position, sparking conversations about its "growth tech stock" valuation.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum driven by its announcement of a record total contract value exceeding a billion and a major new collaboration in genomic testing with Northwestern Medicine. The community is actively discussing the company's AI-driven growth, strategic partnerships, and Cathie Wood's recent share acquisitions, leading to speculation about further gains in the precision medicine sector.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is experiencing significant trending activity following a strong earnings report that propelled its share price upward, fueling speculation of a short squeeze. However, this momentum has met with strong opposing views and a sharp pullback, as recent indications of disappointing holiday sales and a tempered forward outlook trigger investor apprehension regarding its sustained valuation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after announcing preliminary quarterly and full-year results that significantly beat revenue expectations, sparking strong bullish sentiment across the community. Investors are keenly discussing the impressive growth, coupled with high analyst price targets and the potential for a rally driven by the stock's low free float. However, some continue to voice concerns regarding the company's cash reserves and the ongoing risk of dilution.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is generating buzz due to a recently announced manufacturing partnership designed to boost production and margins. This operational catalyst is fueling speculation around a potential short squeeze on its low float, with the community actively debating the stock's dramatic price swings against concerns over potential dilution from a private placement.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to a new partnership and pre-production order with a major U.S. defense contractor, signaling a potential larger military contract for AI-powered situational awareness in combat vehicles. The community is buzzing with anticipation for this significant defense deal, viewing OSS as an undervalued leader in the high-growth Edge AI and defense sectors with a remarkably low float and strong cash position after its recent strategic asset sale.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed following recent FDA approval of ORLADEYO oral pellets for pediatric hereditary angioedema (HAE) and the early termination of the HSR waiting period for its Astria Therapeutics acquisition. Despite these positive developments and high analyst price targets, community sentiment expresses frustration over the stock's muted price action, often attributing it to significant short interest and past management. Investors are now keenly focused on the upcoming CEO transition to Charlie Gayer, hoping new leadership will unlock perceived undervaluation and better reflect the company's progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phreesia, Inc. (NYSE:PHR) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have received a consensus rating of "Moderate Buy" from the eighteen research firms that are covering the stock, Marketbeat Ratings reports. One...

Phreesia, Inc. (NYSE:PHR) Short Interest Down 30.2% in December

Phreesia, Inc. (NYSE:PHR - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 2,427,866 shares, a decline of...

Capricorn Fund Managers Ltd Takes Position in Phreesia, Inc. $PHR

Capricorn Fund Managers Ltd acquired a new position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The...

Phreesia (NYSE:PHR) Sees Strong Trading Volume - Here's Why

Phreesia (NYSE:PHR) Sees Strong Trading Volume - Should You Buy...

Mizuho Lowers Phreesia (NYSE:PHR) Price Target to $28.00

Mizuho lowered their price target on Phreesia from $36.00 to $28.00 and set an "outperform" rating on the stock in a report on Wednesday...

Phreesia (PHR) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Phreesia (PHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Why Phreesia Stock Plummeted by 23% Today

Key PointsInvestors enthusiastically traded out of the stock, despite its good performance across all three business lines...

Citigroup Issues Pessimistic Forecast for Phreesia (NYSE:PHR) Stock Price

Citigroup reduced their price objective on Phreesia from $34.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday...

JPMorgan Chase & Co. Cuts Phreesia (NYSE:PHR) Price Target to $29.00

JPMorgan Chase & Co. dropped their price target on shares of Phreesia from $32.00 to $29.00 and set an "overweight" rating on the stock in a research report on Tuesday...

Phreesia (NYSE:PHR) Reaches New 52-Week Low - Here's Why

Phreesia (NYSE:PHR) Hits New 12-Month Low - What's Next...

Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.

Phreesia Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$17.23
Prev Close	$16.90
Open	$17.15
Dividend Yield	0.00%
50-Day Moving Average	$19.23
Beta	1.55
Avg. Volume	1.82M
PE Ratio	-179.29

52-Week High	$32.76
52-Week Low	$15.41
Market Capitalization	$1.02B
EPS (Annual)	-$1.02
Price to Book	3.24
Revenue Per Employee	$201,639.29
Enterprise Value/EBITDA	N/A

PHR
Phreesia Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHR News

PHRPhreesia Inc